TY - JOUR
T1 - The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis
T2 - A review
AU - Hansson, Oskar
AU - Mikulskis, Alvydas
AU - Fagan, Anne M.
AU - Teunissen, Charlotte
AU - Zetterberg, Henrik
AU - Vanderstichele, Hugo
AU - Molinuevo, Jose Luis
AU - Shaw, Leslie M.
AU - Vandijck, Manu
AU - Verbeek, Marcel M.
AU - Savage, Mary
AU - Mattsson, Niklas
AU - Lewczuk, Piotr
AU - Batrla, Richard
AU - Rutz, Sandra
AU - Dean, Robert A.
AU - Blennow, Kaj
N1 - Publisher Copyright:
© 2018 the Alzheimer's Association
PY - 2018/10
Y1 - 2018/10
N2 - Introduction: Cerebrospinal fluid (CSF) biomarkers have the potential to improve the diagnostic accuracy of Alzheimer's disease, yet there is a lack of harmonized preanalytical CSF handling protocols. Methods: This systematic review summarizes the current literature on the influence of preanalytical variables on CSF biomarker concentration. We evaluated the evidence for three core CSF biomarkers: β-amyloid 42, total tau, and phosphorylated tau. Results: The clinically important variables with the largest amount of conflicting data included the temperature at which samples are stored, the time nonfrozen samples can be stored, and possible effects of additives such as detergents, blood contamination, and centrifugation. Conversely, we discovered that there is consensus that tube material has a significant effect. Discussion: A unified CSF handling protocol is recommended to reduce preanalytical variability and facilitate comparison of CSF biomarkers across studies and laboratories. In future, experiments should use a gold standard with fresh CSF collected in low binding tubes.
AB - Introduction: Cerebrospinal fluid (CSF) biomarkers have the potential to improve the diagnostic accuracy of Alzheimer's disease, yet there is a lack of harmonized preanalytical CSF handling protocols. Methods: This systematic review summarizes the current literature on the influence of preanalytical variables on CSF biomarker concentration. We evaluated the evidence for three core CSF biomarkers: β-amyloid 42, total tau, and phosphorylated tau. Results: The clinically important variables with the largest amount of conflicting data included the temperature at which samples are stored, the time nonfrozen samples can be stored, and possible effects of additives such as detergents, blood contamination, and centrifugation. Conversely, we discovered that there is consensus that tube material has a significant effect. Discussion: A unified CSF handling protocol is recommended to reduce preanalytical variability and facilitate comparison of CSF biomarkers across studies and laboratories. In future, experiments should use a gold standard with fresh CSF collected in low binding tubes.
KW - Alzheimer's disease diagnosis
KW - Biomarkers
KW - Cerebrospinal fluid
KW - Phosphorylated tau
KW - Preanalytical variables
KW - Total tau
KW - β-Amyloid 42
UR - http://www.scopus.com/inward/record.url?scp=85054153726&partnerID=8YFLogxK
U2 - 10.1016/j.jalz.2018.05.008
DO - 10.1016/j.jalz.2018.05.008
M3 - Review article
C2 - 29940161
AN - SCOPUS:85054153726
SN - 1552-5260
VL - 14
SP - 1313
EP - 1333
JO - Alzheimer's and Dementia
JF - Alzheimer's and Dementia
IS - 10
ER -